Myelos Neurosciences Overview
- Year Founded
-
1994
- Status
-
Acquired/Merged
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$35M
Myelos Neurosciences General Information
Description
Developer of therapeutics for neuropathic pain, peripheral neuropathy and neurodegenerative central nervous system disorders. The company provides peptide therapy to treat nervous system disorders and related degenerative diseases to treat pain syndromes and peripheral neuropathies.
Contact Information
Website
www.myelos.comCorporate Office
- 4940 Carroll Canyon Road
- Suite M
- San Diego, CA 92121
- United States
Corporate Office
- 4940 Carroll Canyon Road
- Suite M
- San Diego, CA 92121
- United States
Myelos Neurosciences Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Merger/Acquisition | 19-Mar-2001 | $35M | Completed | Generating Revenue | ||
| 1. Early Stage VC | Completed | Startup |
Myelos Neurosciences Patents
Myelos Neurosciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20100260734-A1 | Method of stimulating prosaposin receptor activity | Inactive | 09-Mar-2001 | ||
| US-7135461-B1 | Having between 17 and 40 d-linked amino acids; improved proteolytic enzyme resistance; neurotrophic activity | Inactive | 16-Jun-2000 | ||
| US-7109168-B1 | Neurotrophic peptides exhibiting increased metabolic stability while retaining biological activity | Inactive | 16-Jun-2000 | ||
| US-7115571-B1 | Of given amino acid sequence; d-amino acid linkage makes peptides resistant to proteolytic degradation in vivo; same activity as native il-3 and also have neurotrophic activity | Inactive | 16-Jun-2000 | ||
| US-7754688-B2 | For promoting neurite outgrowth or myelination | Inactive | 16-Jun-1999 | A61K38/10 |
Myelos Neurosciences Former Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Yellowstone Capital Partners | PE/Buyout | Minority |
Myelos Neurosciences FAQs
-
When was Myelos Neurosciences founded?
Myelos Neurosciences was founded in 1994.
-
Where is Myelos Neurosciences headquartered?
Myelos Neurosciences is headquartered in San Diego, CA.
-
What industry is Myelos Neurosciences in?
Myelos Neurosciences’s primary industry is Therapeutic Devices.
-
Is Myelos Neurosciences a private or public company?
Myelos Neurosciences is a Private company.
-
What is the current valuation of Myelos Neurosciences?
The current valuation of Myelos Neurosciences is .
-
What is Myelos Neurosciences’s current revenue?
The current revenue for Myelos Neurosciences is .
-
Who are Myelos Neurosciences’s investors?
Yellowstone Capital Partners has invested in Myelos Neurosciences.
-
When was Myelos Neurosciences acquired?
Myelos Neurosciences was acquired on 19-Mar-2001.
-
Who acquired Myelos Neurosciences?
Myelos Neurosciences was acquired by Savient Pharmaceuticals.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process